Mullally lab members go to Cold Spring Harbor Laboratory Retreat April 22, 2020 Related Posts Q&A with Brigham Principal Investigator and Hematologist/Oncologist Ann Mullally Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation Dr. Mullally speaks at ESH MPN conference in Estoril, Portugal
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
